Nalaganje...
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
Hyperglycemia is an undisputed epidemiological risk factor for microvascular complications in both type 1 and type 2 diabetes, integral in their causal pathways. Importantly, interventions that reduce the hyperglycemic burden in patients with either type of diabetes reduce the risk of microvascular...
Shranjeno v:
| izdano v: | J Pharm Policy Pract |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8048355/ https://ncbi.nlm.nih.gov/pubmed/33858511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40545-020-00295-3 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|